secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022325
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers
--------------------------------------------------------------------------------

- Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.
- Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.
- Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.
- Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.
- Hired Philip Stocton as Senior Director of Sales and added two regional sales managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/0001493152-25-022325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer